Related Experiment Videos
[Hepatitis C antibodies in groups at epidemic risk]
M D Sailov1, M K Mamedov, N T Gaibov
1National Center of Oncology, Medical University, Baku, Azerbaijan.
Insights
This study investigated hepatitis C virus (HCV) and Hepatitis B surface antigen (HBsAg) in various patient groups. High rates of anti-HCV were found in acute virus hepatitis patients.
Area of Science:
- Virology
- Immunology
- Epidemiology
Context:
- Hepatitis C virus (HCV) and Hepatitis B virus (HBV) pose significant global health challenges.
- Accurate serological detection is crucial for diagnosis and management of viral hepatitis.
- Understanding the prevalence of these infections in diverse patient populations is essential for public health strategies.
Purpose:
- To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) and Hepatitis B surface antigen (HBsAg) in patients with acute virus hepatitis, sexually transmitted diseases, psychiatric disorders, pulmonary tuberculosis, and oncological diseases.
- To assess the utility of solid-phase enzyme immunoassay in detecting these viral markers across different clinical cohorts.
Summary:
- Solid-phase enzyme immunoassay was used to screen blood sera from various patient groups.
- Anti-HCV antibodies were detected in 9.1% of acute virus hepatitis patients and HBsAg in 67.8%.
- Lower but notable percentages of anti-HCV and HBsAg were found in patients with sexually transmitted diseases, psychiatric disorders, pulmonary tuberculosis, and malignant tumors.
Impact:
- Highlights the high co-occurrence of HCV and HBV markers in acute viral hepatitis patients.
- Suggests the need for routine screening of viral hepatitis markers in patients with other significant comorbidities.
- Provides epidemiological data that can inform targeted screening and intervention programs for viral hepatitis.
Abstract:
Blood sera from patients with acute virus hepatitis, sexually transmitted diseases, psychiatric and oncological diseases and pulmonary tuberculosis were studied for the presence of antibodies to hepatitis C virus (anti-HCV) and HBsAg with the use of solid-phase enzyme immunoassay. Anti-HCV were detected, respectively, in 9.1% and 67.8% of patients with acute virus hepatitis, in 5.7% and 6.1% of patients with sexually transmitted diseases, in 7.5% and 9.2% of psychiatric patients, in 7.5% and 13% with pulmonary tuberculosis and malignant tumors.